Advertisement
Advertisement

Read Now: News and Research From ICAAC 2014

Cure Rates With Pipeline HCV Drugs: Reports From AASLD

November/December 2012

 < Prev  |  1  |  2  |  3  |  4 

References

Unless stated otherwise, all references are to the 63 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 9-13 November 2012, Boston, Massachusetts. Abstract can be viewed online using the itinerary planner on the conference website. Free login required.

  1. Lawitz E, Poordad F, Kowdley KV, et al. A 12-week interferon-free regimen of ABT-450/r, ABT-072 and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naive HCV IL28B CC genotype-1-infected subjects. 47th Annual Meeting of the European Association for the Study of the Liver (EASL). 18-22 April 2012, Barcelona, Spain. Abstract 13.
  2. Zeuzem S, Soriano V, Asselah T, et al. Interferon (IFN)-free combination treatment with the HCV NS3/4A protease inhibitor faldaprevir (BI 201335) and the non-nucleoside NS5B inhibitor BI 207127± ribavirin: final results of SOUND-C2 and predictors of response. 63rd AASLD, 2012, Boston. Abstract 232.
  3. Gilead Press release. Gilead announces sustained virologic response rate of 78% from phase 3 study of sofosbuvir for genotype 2/3 hepatitis C infected patients. (27 November 2012).
  4. Gane EJ, Stedman CJ, Hyland RH et al. Once daily sofosbuvir (GS-7977) regimens in HCV genotype 1-3: The ELECTRON trial. 63rd AASLD, 2012, Boston. Abstract 229.
  5. Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT 267, ABT-333, and ribavirin achieves SVR12 Rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection. 63rd AASLD, 2012, Boston. Abstract LB-1.
  6. Soriano V, Gane EJ, Angus P, et al. Efficacy and safety of the interferon-free combination of faldaprevir (BI 201335)+ BI 207127 ± ribavirin in treatment-naive patients with HCV GT-1 and compensated liver cirrhosis: results from the SOUND-C2 study. 63rd AASLD, 2012, Boston. Abstract 84.
  7. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al; AI444040 Study Group. High rate of sustained virologic response with the all-oral combination of daclatisvir (NS5a inhibitor) plus sofosbuvir (nucleotide NS5b inhibitor) with or without ribavirin, in treatment-naive patients chronically infected with HCV GT 1, 2, or 3. 63rd AASLD, 2012, Boston. Abstract LB-2.
  8. Everson GT, Sims KD, Rodriguez-Torres M, et al. An interferon-free, ribavirin-free 12-week regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 yielded SVR4 of 94% in treatment-naive Patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection. 63rd AASLD, 2012, Boston. Abstract LB-3.
  9. Gane EJ, Stedman CJ, Hyland RH et al. Once daily sofosbuvir (GS-7977) regimens in HCV genotype 1-3: The ELECTRON trial. 63rd AASLD, 2012, Boston. Abstract 229.
  10. Osinusi A, Heytens L, Lee YJ, et al. High efficacy of GS-7977 in combination with low or full dose ribavirin for 24 weeks in difficult to treat HCV infected genotype 1 patients. 63rd AASLD, 2012, Boston. Abstract LB-4.
  11. Sulkowski MS, Jacobson IM, Gane EJ. The safety of telaprevir in the absence of interferon and/or ribavirin: analysis of on-treatment data from the ZENITH trial. 63rd AASLD, 2012, Boston. Abstract 786.
  12. Lok AS, Gardiner DF, Hézode C, et al. Sustained virologic response in chronic HCV genotype (GT)1-infected null responders with combination of daclatisvir (DCV; NS5a inhibitor) and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV). 63rd AASLD, 2012, Boston. Abstract 79.
  13. Feld JJ, Jacobson IM, Jensen DM, et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine and ribavirin with or without peginterferon alfa-2a (40KD) in genotype 1-infected partial and null responders: results from the MATTERHORN study. 63rd AASLD, 2012, Boston. Abstract 81.
  14. Izumi N, Lataillade M, Chayama K, et al; D-LITE Study Team. First report of peginterferon lambda/ribavirin in combination with either daclatasvir or asunaprevir in HCV genotype 1 Japanese patients: early sustained virologic response (SVR4) results from the D-LITE Japanese substudy. 63rd AASLD, 2012, Boston. Abstract 284.
  15. Vierling JM, Lataillade M, Gane EJ, et al; D-LITE Study Team. Sustained virologic response (SVR12) in HCV genotype 1 patients receiving peginterferon lambda in combination with ribavirin and either daclatasvir or asunaprevir: interim results from The D-LITE study. 63rd AASLD, 2012, Boston. Abstract LB-9.
  16. Muir A, Hilson J, Gray T, et al; EMERGE Study Group. Peginterferon lambda-1a (lamdba) compared with peginterferon alfa-2a (alfa) in treatment naive patients with HCV genotypes 1 or 4: SVR24 results from EMERGE phase 2b. 63rd AASLD, 2012, Boston. 214.
  17. Thompson A, Shiffman M, Rossaro L, et al. Six weeks of an NS5a inhibitor (GS-5885) and a protease inhibitor (GS-9451) plus peginterferon and ribavirin achieves high SVR4 rates in genotype 1 IL28B CC treatment naive hepatitis C virus patients: interim results of a prospective, randomized trial. 63rd AASLD, 2012, Boston. Abstract 759.
  18. Jacobson IM, Jensen DM, Pol S, et al. Safety and efficacy of ritonavir-boosted danoprevir (DNVr), peginterferon alfa-2a (40KD) and ribavirin with or without mericitabine in genotype 1-infected treatment-experienced patients with advanced hepatic fibrosis: the MATTERHORN study. 63rd AASLD, 2012, Boston. Abstract 82.
  19. Hassanein T, Lawitz E, Crespo I, et al; the ATOMIC Investigators. Once-daily sofosbuvir (GS-7977) plus PEG/RBV in treatment-naive patients with HCV genotype 1, 4, and 6 infection: The ATOMIC study. 63rd AASLD, 2012, Boston. Abstract 230.
  20. Hézode C, Shiffman ML, Cooper C, et al. Ritonavir-boosted danoprevir plus PegIFN alfa-2a/ ribavirin (P/R) demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment-naive patients with HCV genotype 4 infection in the DAUPHINE study. 63rd AASLD, 2012, Boston. Abstract 760.
  21. Rodriguez-Torres M, Ishak L, Fontana D, et al; EMERGE Study Group. Peginterferon lambda-1a (LAMBDA) shows superior viral response with improved safety and tolerability versus peginterferon alfa-2a (alfa-2a) in patients with chronic HCV infection (G 1/2/3/4): EMERGE phase 2b through week 12 results. 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012), 16-19 February 2012, Taipei, Taiwan.
  22. Sulkowski MS, Sherman KE, Soriano V, et al; Study 110 Team. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HIV/HCV co-infected patients: SVR24 final study results. 63rd AASLD, 2012, Boston. Abstract 54.
  23. ClinicalTrials.gov. Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-Infected Subjects.
  24. Kirby B, Mathias A, Rossi S, et al. No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla®, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. 63rd AASLD, 2012, Boston. 1877.
  25. Hézode C, Dorival C, Zoulim F, et al. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 455 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. 63rd AASLD, 2012, Boston. Abstract 51.
  26. Gallegos-Orozco JF, Chervenak AE, Carey EJ, et al. Liver transplant center focused experience with peginterferon alfa-2a, ribavirin and telaprevir therapy in patients with genotype 1 hepatitis C cirrhosis. 63rd AASLD, 2012, Boston. Abstract 53.
  27. Burton JR, O'Leary J, Verna EC, et al. A multicenter study of protease inhibitor-triple therapy in HCV-infected liver transplant recipients: report from the CRUSH-C group. 63rd AASLD, 2012, Boston. Abstract 211.
  28. Fontana RJ, Bifano M, Hindes R, et al. First ever successful use of daclatasvir and GS-7977, an interferon-free oral regimen, in a liver transplant recipient with severe recurrent hepatitis. 63rd AASLD, 2012, Boston. Abstract 694.
  29. Mathias A, Cornpropst M, Clemons D, et al. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers. 63rd AASLD, 2012, Boston. Abstract 1869.
  30. Ouwerkerk-Mahadevan S, Simion A, Mortier S, et al. No clinically significant interaction between the investigational HCV protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus. 63rd AASLD, 2012, Boston. Abstract 80.

Links to other websites are current at date of posting but not maintained.

 < Prev  |  1  |  2  |  3  |  4 



This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
 

 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement